Æ÷½ºÅÍ Á¦Ãâ ¸¶°¨ÀÏ : 2024³â 9¿ù 15ÀÏ
Á¦ÃâµÈ Æ÷½ºÅÍ °³¿ä´Â ¸ðµÎ °úÇÐ ÀÚ¹®À§¿øÈ¸¿¡ ÀÇÇØ ½É»çµÇ¸ç, ½ÅûÀÚ¿¡°Ô´Â ±× °á°ú°¡ Å뺸µË´Ï´Ù.
½ÂÀÎµÈ ½ÅûÀÚ¿¡°Ô´Â ÇÊ¿äÇÑ Á¤º¸°¡ ¸ðµÎ Á¦°øµË´Ï´Ù.
°³¿ä ³»¿ë :
- ÀüºÎ ¿µ¾î·Î ±âÀçÇÒ °Í
- »ïÀÎĪÀ¸·Î ±â¼úÇÒ °Í
- ŸÀÌÆ²¡¤ÀúÀÚ¸í¡¤ÀúÀÚÀÇ ¼Ò¼Óó¸¦ ±âÀçÇÒ °Í
- 100-200 ¿öµå À̳»
- ȸÀÇ·Ï ¹× À¥»çÀÌÆ®¿¡ ´ëÇÑ Á÷Á¢ °ÔÀç¿¡ ÀûÇÕÇÑ Çü½ÄÀ¸·Î ÇÒ °Í
- ÄÁÆÛ·±½º ÁÖÁ¦¿¡ °ü·ÃÇÒ °Í
¾ÆÁ¨´Ù ÅäÇÈ
- Circulating Biomarkers: cfDNA, RNA, EVs, Others
¼øÈ¯ ¹ÙÀÌ¿À¸¶Ä¿ : cfDNA, RNA, EV µî
- Novel Biomarker Classes for Diagnostics Development
Áø´ÜÇÐ ¹ßÀüÀ» À§ÇÑ ½Å±Ô ¹ÙÀÌ¿À¸¶Ä¿ Ŭ·¡½º
- Regulatory Landscape for Diagnostics in the US, circa 2024
¹Ì±¹¿¡¼ Áø´ÜÇÐÀÇ ±ÔÁ¦ »óȲ(2024³â°æ)
- Technologies for Deploying Biomarkers into Novel Diagnostics Classes
½Å±Ô Áø´Ü Ŭ·¡½º¿¡ ´ëÇÑ ¹ÙÀÌ¿À¸¶Ä¿ µµÀÔÀ» À§ÇÑ ±â¼ú
ÀúÀÛ±Ç
°³¿ä¸¦ Á¦ÃâÇÑ ¹ßÇ¥ÀÚ/°³ÀÎÀº °³¿ä¿¡ ±âÀçµÈ ³»¿ë¿¡ ´ëÇØ ¸ðµç Ã¥ÀÓÀ» Áö¸ç, °øÀúÀÚ Àü¿øµµ ÀÌ »ç½ÇÀ» ¾Ë°í ÀÖ´Â °ÍÀ¸·Î ÇÕ´Ï´Ù. Á¦ÃâÀÚÀÇ °æ·Â¼ ¹× ¿ä¾à¡¤°³¿ä´Â ÀÌ À¥»çÀÌÆ® ¹× ÄÁÆÛ·±½º ÀÚ·á¿¡ »ç¿ëµÉ ¼ö ÀÖÀ¸¹Ç·Î ¾çÇØ ¹Ù¶ø´Ï´Ù.
|